Zafirlukast: Efficacy in asthmatic adults and children

Clinical and Experimental Allergy Reviews

Volumn 1, Issue 3, 2001, Pages 274-279

  Bonuccelli, C M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28144449176     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-9725.2001.t01-1-00013.x     Document Type: Article

References (25)

1. Spector SL, Smith LJ, Glass M et al. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
2. Fish JE, Kemp JP, Lockey RF et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19:675-90.
3. Nathan RA, Bernstein JA, Bielory L et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998; 102:935-42.
4. Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000; 55:478-83.
5. 2-agonists. Eur Respir J 1997; 10 (Suppl. 25):419S-20.
6. Ringdal N, Whitney JG, Summerton L. Problems with inhaler technique and patient preference for oral therapy - tablet zafirlukast vs. inhaled beclomethasone. Am J Resp Crit Care Med 1998; 157:A416.
7. Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol 2000; 11:49-55.
8. Chung KF, Naya I. Compliance with an oral asthma medication: a pilot study using an electronic monitoring device. Respir Med 2000; 94:852-8.
9. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Non-compliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051-7.
10. Mawhinney H, Spector S, Kinsman RA et al. Compliance in clinical trials of two nonbronchodilator, antiasthma medications. Ann Allergy 1991; 66:294-9.
11. Rand CS, Wise RA, Nides M et al. Metered dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146:1559-64.
12. Spector SL, Kinsman R, Mawhinney H et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials. J Allergy Clin Immunol 1986; 77:65-70.
13. Suissa S, Dennis R, Erust P et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized double blind placebo controlled trial. Ann Intern Med 1997; 126:177-83.
14. Pearlman DS, Lampl KL, Dowling PJ et al. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000; 22:732-47.
15. Finn A, Bonuccelli CM, Traxler BM et al. Zafirlukast improves asthma control in children treated with and without inhaled corticosteroids. Pediatr Res 2000; 47:16A [abstract 92].
16. Virchow JC, Prasse A, Naya I et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162: 578-85.
17. Nayak AS, Anderson P, Kharous BL et al. Addition of zafirlukast compared with a doubled dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids. Eur Respir J 1998; 12:361S [abstract P2388].
18. Ringdal N, White M, Harris A et al. Addition of zafirlukast (ACCOLATE™) compared with a double-dose of inhaled corticosteroids in patients with reversible airways obstruction symptomatic on inhaled corticosteroids. Am J Respir Crit Care Med 1999; 59:639.
19. Jones PW, Silverman S, Naya I et al. Greater improvements in quality of life (QOL) over 12 months with zafirlukast 20 mg bd plus low dose steroids vs. double-dose steroids in patients with greater QOL impairment. Eur Respir J 1999; 14:340s [abstract P2289].
20. Myamoto T. Efficacy and safety of zafirlukast (ACCOLATE™) in asthmatic patients treated with and without corticosteroids. Am J Respir Crit Care Med 1999; 159:A640.
21. Kemp JP, Korenblat PE, Scherger JE. Zafirlukast in clinical practice: overall results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. J Fam Pract 1999; 48:425-32.
22. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-3.
23. Silverman RA, Miller CJ, Chen Y et al. Zafirlukast reduces relapses and treatment failures after an acute asthma episode. Chest 1999; 116:2965.
24. Phipatanakul W, Eggleston PA, Conover-Walker MK et al. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol 2000; 105:704-10.
25. Corren J, Spector S, Fuller L et al. Effect of zafirlukast (Accolate®) on pulmonary responses to natural cat allergen exposure. J Allergy Clin Immunol 1999; 103:S134 [abstract 509].